Fibrodysplasia Ossificans Progressiva: Drugs
(asked on 29th October 2021) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answers of 22 October 2021 to Questions 56489 and 56878, on Fibrodysplasia Ossificans Progressiva: Health Services, what the status is of the highly specialised technologies guidance on Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva.
Answered by
Maria Caulfield
Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The National Institute for Health and Care Excellence is in the early stages of developing highly specialised technologies guidance on palovarotene and is in discussion with the manufacturer regarding timings for this appraisal. The publication date for guidance is to be confirmed.